TherapeuticsMD Reports Strong 2025: License Revenue Jumps 71.6%, Net Loss Significantly Narrows
TXMD has more than doubled off its 52-week low of $0.84.
Summary
TherapeuticsMD announced its 2025 10-K results, reporting $3.02 million in license revenue, a substantial 71.6% increase from 2024, and a net loss per share of $0.06 from continuing operations. The company significantly narrowed its overall net loss to $(0.569) million for the year, a marked improvement from $(2.181) million in 2024, alongside an improved loss from operations. These results demonstrate positive momentum following the company's strategic shift in December 2022 to a pharmaceutical royalty model, indicating successful execution and improved financial health. The material increase in royalty-driven revenue and reduced operating losses are key indicators for investors. Moving forward, traders should monitor the company's ability to maintain this revenue growth and resolve ongoing contingent and legal disputes with Mayne Pharma, which could affect future royalty streams.
At the time of this announcement, TXMD was trading at $1.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23M. The 52-week trading range was $0.84 to $2.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.